This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Verenium's CEO Presents At Jefferies 2012 Global Industrial And Aerospace And Defense Conference (Transcript)

Verenium Corporation (VRNM)

Jefferies 2012 Global Industrial and Aerospace and Defense Conference Transcript

August 7, 2012 10:30 AM ET

Executives

Jamie Levine - Chief Executive Officer

Analysts

Presentation

Unidentified Analyst

Hi, everybody. We could get going to the next presentation here. I’d like to introduce the present CEO of Verenium Corporation, Jamie Levine, and we’re gong have a breakout session in the [Gilliard] room following this presentation.

Jamie Levine

Thanks everyone in the room and listen by the webcast. I’m Jamie Levine, CEO of Verenium Corporation. I’ll be making some forward-looking statements today and we just advise you to look at our statement here and in our SEC fillings for the associated risks of making those statements.

So I’d like to start with just a brief overview in term of what we are as a company and then a bit about our industry, our products and our future. If look at Verenium today at a glance. We have a sole focus on industrial enzymes market and I’ll talk about what that is in a moment.

But for us, it’s very much about brining a unique and patented enzyme discovery and evaluation platform, which allows us to create highest preforming products, which is a proven model.

We sold $55 million of our products in the last 12 months and in the short-term the focus is on selling more of those products and in the medium-term, it’s about commercializing products out of our pipeline.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,680.53 +84.18 0.48%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs